RISK OF HYPERTENSION (HTN) AND MALIGNANT HYPERTENSION (MHTN) IN PATIENTS TREATED FOR MULTIPLE MYELOMA (MM)
(Abstract release date: 05/19/16)
EHA Library. Chari A. 06/09/16; 134882; PB1982
Dr. Ajai Chari
Contributions
Contributions
Abstract
Abstract: PB1982
Type: Publication Only
Background
HTN is commonly reported in patients (Pts) with MM and may be associated with older age, disease-related complications, or sequelae of MM treatments.
Aims
To evaluate incidence rates (IR) of HTN and mHTN in treated MM Pts in the United States and the risk of mHTN development in MM Pts with pre-existing HTN.
Methods
Newly-treated adult MM Pts were identified from Truven MarketScan claims database from 1/1/05 to 3/31/14 using ICD-9 codes to identify disease state, HTN, mHTN, and comorbidities. Inclusion criteria were new diagnosis of MM with start of MM treatment, ≥12 months continuous enrollment (CE) prior to diagnosis, prescription drug coverage, and ≥30 days of CE following initial diagnosis. Non-MM Pts were matched on age (within +/- 5 yrs), gender, and distribution of index dates to MM Pts. Risk of HTN and mHTN based on existing HTN and other cardiovascular (CV) comorbidities were evaluated over time.
Results
Study included 7895 MM Pts (38% with HTN history) and 23685 non-MM patients (24% HTN history). The IR of HTN in MM and non-MM Pts was 260 and 178 per 1000 person-years (PYRs), respectively. The IR of mHTN in Pts with and without HTN history were 10.25 and 3.29 per 1000 PYRs, respectively for MM patients; 4.25 and 1.88 per 1000 PYRs, respectively for non-MM Pts. Risk of HTN (HR: 1.30; 95% CI: 1.22, 1.37) increased 30% in MM vs. non-MM Pts. MM Pts with (HR: 1.90; 95% CI: 1.26, 2.87) or without (HR: 1.54; 95% CI: 1.04, 2.28) HTN history had a higher risk of mHTN events during the observation period vs. non-MM Pts. In MM Pts with HTN history, the risk of mHTN was significantly increased with the following comorbid conditions: cardiomyopathy (HR: 2.79; 95% CI: 1.20, 6.48), renal failure (HR: 2.13; 95% CI: 1.36, 3.34), and diabetes mellitus (HR: 1.59; 95% CI: 1.05, 2.39).
Conclusion
This study confirms that incidence of HTN and mHTN is higher in newly-treated MM Pts vs non-MM Pts. Existing HTN is a risk factor for MM Pts developing mHTN. Management of CV risk factors and comorbidities in MM Pts is important based on the increased risk of HTN and mHTN among these Pts.
Session topic: E-poster
Keyword(s): Comorbidities, Multiple myeloma
Type: Publication Only
Background
HTN is commonly reported in patients (Pts) with MM and may be associated with older age, disease-related complications, or sequelae of MM treatments.
Aims
To evaluate incidence rates (IR) of HTN and mHTN in treated MM Pts in the United States and the risk of mHTN development in MM Pts with pre-existing HTN.
Methods
Newly-treated adult MM Pts were identified from Truven MarketScan claims database from 1/1/05 to 3/31/14 using ICD-9 codes to identify disease state, HTN, mHTN, and comorbidities. Inclusion criteria were new diagnosis of MM with start of MM treatment, ≥12 months continuous enrollment (CE) prior to diagnosis, prescription drug coverage, and ≥30 days of CE following initial diagnosis. Non-MM Pts were matched on age (within +/- 5 yrs), gender, and distribution of index dates to MM Pts. Risk of HTN and mHTN based on existing HTN and other cardiovascular (CV) comorbidities were evaluated over time.
Results
Study included 7895 MM Pts (38% with HTN history) and 23685 non-MM patients (24% HTN history). The IR of HTN in MM and non-MM Pts was 260 and 178 per 1000 person-years (PYRs), respectively. The IR of mHTN in Pts with and without HTN history were 10.25 and 3.29 per 1000 PYRs, respectively for MM patients; 4.25 and 1.88 per 1000 PYRs, respectively for non-MM Pts. Risk of HTN (HR: 1.30; 95% CI: 1.22, 1.37) increased 30% in MM vs. non-MM Pts. MM Pts with (HR: 1.90; 95% CI: 1.26, 2.87) or without (HR: 1.54; 95% CI: 1.04, 2.28) HTN history had a higher risk of mHTN events during the observation period vs. non-MM Pts. In MM Pts with HTN history, the risk of mHTN was significantly increased with the following comorbid conditions: cardiomyopathy (HR: 2.79; 95% CI: 1.20, 6.48), renal failure (HR: 2.13; 95% CI: 1.36, 3.34), and diabetes mellitus (HR: 1.59; 95% CI: 1.05, 2.39).
Conclusion
This study confirms that incidence of HTN and mHTN is higher in newly-treated MM Pts vs non-MM Pts. Existing HTN is a risk factor for MM Pts developing mHTN. Management of CV risk factors and comorbidities in MM Pts is important based on the increased risk of HTN and mHTN among these Pts.
Session topic: E-poster
Keyword(s): Comorbidities, Multiple myeloma
Abstract: PB1982
Type: Publication Only
Background
HTN is commonly reported in patients (Pts) with MM and may be associated with older age, disease-related complications, or sequelae of MM treatments.
Aims
To evaluate incidence rates (IR) of HTN and mHTN in treated MM Pts in the United States and the risk of mHTN development in MM Pts with pre-existing HTN.
Methods
Newly-treated adult MM Pts were identified from Truven MarketScan claims database from 1/1/05 to 3/31/14 using ICD-9 codes to identify disease state, HTN, mHTN, and comorbidities. Inclusion criteria were new diagnosis of MM with start of MM treatment, ≥12 months continuous enrollment (CE) prior to diagnosis, prescription drug coverage, and ≥30 days of CE following initial diagnosis. Non-MM Pts were matched on age (within +/- 5 yrs), gender, and distribution of index dates to MM Pts. Risk of HTN and mHTN based on existing HTN and other cardiovascular (CV) comorbidities were evaluated over time.
Results
Study included 7895 MM Pts (38% with HTN history) and 23685 non-MM patients (24% HTN history). The IR of HTN in MM and non-MM Pts was 260 and 178 per 1000 person-years (PYRs), respectively. The IR of mHTN in Pts with and without HTN history were 10.25 and 3.29 per 1000 PYRs, respectively for MM patients; 4.25 and 1.88 per 1000 PYRs, respectively for non-MM Pts. Risk of HTN (HR: 1.30; 95% CI: 1.22, 1.37) increased 30% in MM vs. non-MM Pts. MM Pts with (HR: 1.90; 95% CI: 1.26, 2.87) or without (HR: 1.54; 95% CI: 1.04, 2.28) HTN history had a higher risk of mHTN events during the observation period vs. non-MM Pts. In MM Pts with HTN history, the risk of mHTN was significantly increased with the following comorbid conditions: cardiomyopathy (HR: 2.79; 95% CI: 1.20, 6.48), renal failure (HR: 2.13; 95% CI: 1.36, 3.34), and diabetes mellitus (HR: 1.59; 95% CI: 1.05, 2.39).
Conclusion
This study confirms that incidence of HTN and mHTN is higher in newly-treated MM Pts vs non-MM Pts. Existing HTN is a risk factor for MM Pts developing mHTN. Management of CV risk factors and comorbidities in MM Pts is important based on the increased risk of HTN and mHTN among these Pts.
Session topic: E-poster
Keyword(s): Comorbidities, Multiple myeloma
Type: Publication Only
Background
HTN is commonly reported in patients (Pts) with MM and may be associated with older age, disease-related complications, or sequelae of MM treatments.
Aims
To evaluate incidence rates (IR) of HTN and mHTN in treated MM Pts in the United States and the risk of mHTN development in MM Pts with pre-existing HTN.
Methods
Newly-treated adult MM Pts were identified from Truven MarketScan claims database from 1/1/05 to 3/31/14 using ICD-9 codes to identify disease state, HTN, mHTN, and comorbidities. Inclusion criteria were new diagnosis of MM with start of MM treatment, ≥12 months continuous enrollment (CE) prior to diagnosis, prescription drug coverage, and ≥30 days of CE following initial diagnosis. Non-MM Pts were matched on age (within +/- 5 yrs), gender, and distribution of index dates to MM Pts. Risk of HTN and mHTN based on existing HTN and other cardiovascular (CV) comorbidities were evaluated over time.
Results
Study included 7895 MM Pts (38% with HTN history) and 23685 non-MM patients (24% HTN history). The IR of HTN in MM and non-MM Pts was 260 and 178 per 1000 person-years (PYRs), respectively. The IR of mHTN in Pts with and without HTN history were 10.25 and 3.29 per 1000 PYRs, respectively for MM patients; 4.25 and 1.88 per 1000 PYRs, respectively for non-MM Pts. Risk of HTN (HR: 1.30; 95% CI: 1.22, 1.37) increased 30% in MM vs. non-MM Pts. MM Pts with (HR: 1.90; 95% CI: 1.26, 2.87) or without (HR: 1.54; 95% CI: 1.04, 2.28) HTN history had a higher risk of mHTN events during the observation period vs. non-MM Pts. In MM Pts with HTN history, the risk of mHTN was significantly increased with the following comorbid conditions: cardiomyopathy (HR: 2.79; 95% CI: 1.20, 6.48), renal failure (HR: 2.13; 95% CI: 1.36, 3.34), and diabetes mellitus (HR: 1.59; 95% CI: 1.05, 2.39).
Conclusion
This study confirms that incidence of HTN and mHTN is higher in newly-treated MM Pts vs non-MM Pts. Existing HTN is a risk factor for MM Pts developing mHTN. Management of CV risk factors and comorbidities in MM Pts is important based on the increased risk of HTN and mHTN among these Pts.
Session topic: E-poster
Keyword(s): Comorbidities, Multiple myeloma
{{ help_message }}
{{filter}}